Welcome to our dedicated page for CYBIN SEC filings (Ticker: HELP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Cybin Inc., operating as Helus Pharma, reports completion of enrollment in its APPROACH Phase 3 pivotal study of HLP003 as an adjunctive treatment for adults with moderate to severe major depressive disorder. The study enrolled 223 participants on stable antidepressants, randomized 1:1 to HLP003 16 mg or placebo, each given as two doses three weeks apart.
The primary endpoint is change from baseline in MADRS at six weeks, with a key secondary endpoint at 12 weeks, and topline data targeted for Q4 2026. HLP003, an investigational deuterated psilocin analogue, has FDA Breakthrough Therapy Designation and in Phase 2 showed a mean ~23-point MADRS reduction 12 months after two 16 mg doses, with 100% response and 71% remission at a MADRS ≤10 benchmark. Enrollment continues in the EMBRACE pivotal study with rollover into the EXTEND long-term extension, and the disclosure is incorporated into the company’s Form F-10 shelf registration, supported by more than 350 patent applications and over 100 granted patents worldwide.
Helus Pharma, the commercial name of Cybin Inc., completed an underwritten offering of 10,309,280 common shares at US$4.85 per share, raising aggregate gross proceeds of US$50 million. Cantor Fitzgerald & Co. and Barclays Capital Inc. acted as joint bookrunning managers, with Bloom Burton Securities Inc. and Lucid Capital Markets as lead managers; the underwriters received a US$3 million cash commission.
The common shares were sold in the United States and certain other jurisdictions outside Canada under a prospectus supplement to Cybin’s Canadian short form base shelf prospectus, also registered with the SEC on Form F-10. The company plans to use net proceeds to advance HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, HLP005 programs, and for working capital and general corporate needs, with Phase 3 APPROACH data for HLP003 expected in the fourth quarter of 2026.
Cybin Inc., an Ontario, Canada corporation in the health care/biotechnology industry, filed a new notice of an exempt securities offering relying on Rule 506(b) of Regulation D. The issuer was formed over five years ago and lists its principal office in Toronto.
The offering consists of an aggregate of 312,407 restricted share units that vest periodically until July 1, 2029, together with related rights to acquire securities. The date of first sale is stated as July 1, 2026. The total amount sold is reported as $0 USD, and reported finders' fees are $0 USD. For issuer size, Cybin selects the “Decline to Disclose” option for both revenue and aggregate net asset value ranges.
Cybin Inc., an Ontario-based biotechnology corporation, is conducting a private offering of stock options under the Rule 506(b) exemption of Regulation D. The options could generate up to $511,720 in proceeds, representing the maximum potential proceeds from option exercises.
The options are exercisable at $6.61 per share until June 30, 2036, and vest in seven quarterly tranches beginning July 1, 2026. Total amount sold is reported as $0, and the notice lists $0 in finders’ fees.
Helus Pharma, the commercial name of Cybin Inc., reported audited fiscal 2026 results and key pipeline progress. Cash totaled $157.3 million as of March 31, 2026, and the company recently completed a $50 million underwritten offering to support its late-stage programs.
The net loss widened to $148.0 million for the year, driven by higher cash-based operating expenses of $131.7 million as Phase 3 trials for HLP003 and Phase 2 work on HLP004 advanced. The Phase 3 APPROACH study of HLP003 in Major Depressive Disorder has surpassed 88% enrollment, with topline data targeted for Q4 2026, while enrollment is underway in the EMBRACE pivotal study and rollover into the EXTEND durability study continues.
In anxiety, HLP004 delivered a statistically significant ~10‑point improvement on the HAM-A scale at six weeks in a Phase 2 signal detection study, with durable effects to at least six months. Helus is also progressing HLP005 toward candidate selection in the second half of 2027, has added multiple high-profile R&D and medical leaders, and notes supportive U.S. policy signals for psychedelic therapies, including recognition in a White House press release.
Cybin Inc. filed its Annual Report on Form 40-F for the fiscal year ended March 31, 2026, reporting 51,631,804 common shares outstanding as of March 31, 2026. The report attaches the AIF, audited consolidated financial statements, and the MD&A as Exhibits 99.1–99.3. Management concluded that disclosure controls and internal control over financial reporting were effective as of March 31, 2026. The company confirms foreign private issuer status, lists its common shares on Nasdaq under the symbol HELP, and notes it is an emerging growth company.
Helus Pharma, the commercial name of Cybin Inc., has closed an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million. Cantor and Barclays acted as joint bookrunning managers, with Bloom Burton Securities Inc. and Lucid Capital Markets as lead managers.
The company plans to use the net proceeds to advance HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and general corporate purposes. Phase 3 APPROACH data for HLP003 are expected in the fourth quarter of 2026.
Helus Pharma, the commercial name of Cybin Inc., has priced a US$50 million underwritten equity financing and reported strong progress in its lead depression program. The company is selling 10,309,280 common shares at US$4.85 each in a fully underwritten offering, with Cantor and Barclays as joint bookrunners. Helus plans to use the proceeds mainly to advance HLP003, its Phase 3 serotonergic agonist for major depressive disorder, as well as HLP004 for generalized anxiety disorder, HLP005 and general corporate purposes. Separately, the APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, with topline data targeted for the fourth quarter of 2026. Prior Phase 2 data for HLP003 showed a ~23‑point improvement on the Montgomery‑Åsberg Depression Rating Scale at 12 months after two 16 mg doses, with response and remission rates improving over time.
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K highlighting Helus Pharma’s participation in the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026, where its Chief Medical Officer will join a fireside chat available on demand.
The filing also describes Helus Pharma as a clinical-stage company developing proprietary novel serotonergic agonists (NSAs) for mental health conditions, including HLP003 in Phase 3 for adjunctive treatment of major depressive disorder with U.S. FDA Breakthrough Therapy Designation and HLP004 in Phase 2 for generalized anxiety disorder, alongside an expanded NSA research portfolio and standard forward-looking statement cautions.
Cybin Inc., operating as Helus Pharma, furnished a report noting that Interim CEO Eric So will join a fireside chat at the Jefferies Global Healthcare Conference in New York, held June 2–4, 2026. The session will be webcast live on June 4, 2026, at 2:35 p.m. EDT, with a replay available on the company’s investor relations site.
Helus Pharma is described as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety and other mental health conditions. Its lead NSA, HLP003, is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has U.S. FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder. The release includes extensive forward-looking statement cautions and emphasizes that none of the company’s programs have yet been approved by regulators.